Publicacións nas que colabora con Javier Corral De La Calle (22)

2022

  1. Contact pathway in surgical and transcatheter aortic valve replacement

    Frontiers in Cardiovascular Medicine, Vol. 9

2010

  1. Synergism between factor XII -4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction

    Thrombosis and Haemostasis

2009

  1. Antithrombin Cambridge ll (A384S) supports a role for antithrombin deficiency in arterial thrombosis

    Thrombosis and Haemostasis, Vol. 101, Núm. 3, pp. 483-486

2008

  1. AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms

    Haematologica, Vol. 93, Núm. 5, pp. 729-734

  2. Endothelial protein C receptor polymorphisms and risk of myocardial infarction

    Haematologica, Vol. 93, Núm. 9, pp. 1358-1363

  3. Factor VII -323 decanucleotide D/I polymorphism in atrial fibrillation: Implications for the prothrombotic state and stroke risk

    Annals of Medicine, Vol. 40, Núm. 7, pp. 553-559

2007

  1. Prognostic value of annexin A5-1 C/T polymorphism in a long term follow-up after premature myocardial infarction [2]

    Journal of Thrombosis and Haemostasis

  2. The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol

    Journal of Thrombosis and Haemostasis, Vol. 5, Núm. 8, pp. 1701-1706

  3. The pharmacogenetics of antiplatelet drugs

    Current Opinion in Investigational Drugs, Vol. 8, Núm. 3, pp. 213-218

2006

  1. Fluctuations in coagulation activity among patients with atrial fibrillation who are stably anticoagulated

    Future Cardiology, Vol. 2, Núm. 2, pp. 197-203

2005

  1. A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction

    Journal of the American College of Cardiology, Vol. 45, Núm. 1, pp. 25-29

  2. Five prothrombotic polymorphisms and the prevalence of premature myocardial infarction

    Haematologica, Vol. 90, Núm. 3, pp. 421-423

  3. Pharmacogenetics in cardiovascular antithrombotic therapy

    Current Medicinal Chemistry: Cardiovascular and Hematological Agents, Vol. 3, Núm. 4, pp. 357-364

  4. Synergistic association between hypercholesterolemia and the C46T factor XII polymorphism for developing premature myocardial infarction

    Thrombosis and Haemostasis, Vol. 94, Núm. 6, pp. 1294-1299

2004

  1. Effect of factor VII -323 Del/Ins polymorphism on the daily variability of factor VIIc and INR in steady anticoagulated patients with acenocoumarol [3]

    Journal of Thrombosis and Haemostasis

  2. Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation

    Journal of Molecular and Cellular Cardiology, Vol. 37, Núm. 3, pp. 699-704

  3. Short alleles of P-selectin glycoprotein ligand-1 protect against premature myocardial infarction

    American Heart Journal, Vol. 148, Núm. 4, pp. 602-605

2003

  1. Role of factor XIII Val34Leu polymorphism in patients <45 years of age with acute myocardial infarction

    American Journal of Cardiology, Vol. 91, Núm. 10, pp. 1242-1245

  2. The -1C>T mutation in the annexin A5 gene does not affect plasma levels of annexin A5 [2] (multiple letters)

    Blood

2002

  1. A common polymorphism in the annexin V Kozak sequence (-1C>T) increases translation efficiency and plasma levels of annexin V, and decreases the risk of myocardial infarction in young patients

    Blood, Vol. 100, Núm. 6, pp. 2081-2086